Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Renal Transplant Rejection Linked with Risk of cSCC

Clin Exp Dermatol; ePub 2018 Jun 27; Puza, et al

Transplant rejection is associated with both a higher incidence and an accelerated time course for development of cutaneous squamous cell carcinoma (cSCC) following renal transplantation, according to a recent study. Therefore, close dermatological surveillance should be considered following an episode of rejection in this patient population. The Duke Enterprise Data Unified Content Explorer historical database was used to identify patients who had undergone a renal transplant at Duke University Hospital during a 20-year period. Data on patient demographics, transplant dates, first rejection episodes, first cSCC development, medication, laboratory results, and survival were recorded. Researchers found:

  • In total, 1,684 patients were identified, of whom 126 (7.5%) experienced an episode of rejection and 46 (4.0%) developed a cSCC after transplant.
  • The incidence of cSCC was significantly greater in the rejection group, with 8.7% of patients developing cSCC compared with 2.2% in the no-rejection group.
  • Median lag time to cSCC was shorter in the rejection group (2.5 years) than the no-rejection group (4.2 years).


Puza CJ, Myers SA, Cardones AR, Beasley GM, Mosca PJ. The impact of transplant rejection on cutaneous squamous cell carcinoma in renal transplant recipients. [Published online ahead of print June 27, 2018]. Clin Exp Dermatol. doi:10.1111/ced.13699.